WHAT MOTIVATES YOU?

The potential of identifying and investing biotech companies with breakthrough science and disruptive technologies such as Antibody drug conjugate, T cell engager, Radioligand therapy, RNAi, AI-powered tools etc. to address unmet needs.The potential of identifying and investing biotech companies with breakthrough science and disruptive technologies such as Antibody drug conjugate, T cell engager, Radioligand therapy, RNAi, AI-powered tools etc. to address unmet needs.

WHAT’S BEEN THE STEEPEST LEARNING CURVE ON YOUR CAREER JOURNEY SO FAR?

Transition from working in early drug discovery organization at GSK, a multinational drug company, with a well-established regulatory agency in the US to setting up a start-up biotech company in China in 2015, when innovative drug discovery concept was new.

Challenges are multidimensional including re-adjusting to local culture after 25 years gap, lack of regulatory guidance and official communication channels for novel drug modalities in IND-filing.

WHICH TECH TREND ARE YOU MOST EXCITED ABOUT AT THE MOMENT AND WHY?

Multimodality approaches and AIDD tools to address unmet needs in diseases currently lacking effective treatment. We can now tackle targets we used to call “undruggable” since, equipped with disruptive technologies and AIDD tools, we can now interrogate and intervene a disease or pathway in not only protein level, but also at mRNA or DNA level much more efficiently.

WHAT’S THE BEST PIECE OF ADVICE YOU’VE EVER RECEIVED?

Pick a career you have passion about and stay with it. Be adventurous and be humble.

Life is a journey and cherish each day.